Spire Healthcare Group plc (LON:SPI) Announces Dividend of GBX 2.30

Spire Healthcare Group plc (LON:SPI) announced a dividend on Thursday, March 6th, DividendData.Co.Uk reports. Stockholders of record on Thursday, May 22nd will be paid a dividend of GBX 2.30 ($0.03) per share on Friday, June 20th. This represents a dividend yield of 1.29%. The ex-dividend date is Thursday, May 22nd. This is a 9.5% increase from Spire Healthcare Group’s previous dividend of $2.10. The official announcement can be seen at this link.

Spire Healthcare Group Price Performance

Shares of LON:SPI opened at GBX 197.80 ($2.64) on Tuesday. Spire Healthcare Group has a 1-year low of GBX 168.20 ($2.25) and a 1-year high of GBX 270.50 ($3.61). The firm has a market capitalization of £794.30 million, a PE ratio of 28.15, a PEG ratio of 1.06 and a beta of 0.96. The business’s 50 day moving average is GBX 185.44 and its 200-day moving average is GBX 209.93. The company has a current ratio of 0.70, a quick ratio of 0.74 and a debt-to-equity ratio of 62.25.

Spire Healthcare Group (LON:SPI) last announced its quarterly earnings results on Thursday, March 6th. The company reported GBX 8.80 ($0.12) EPS for the quarter. Spire Healthcare Group had a return on equity of 3.82% and a net margin of 1.96%. Sell-side analysts predict that Spire Healthcare Group will post 15.6634747 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Deutsche Bank Aktiengesellschaft decreased their price target on Spire Healthcare Group from GBX 320 ($4.27) to GBX 300 ($4.01) and set a “buy” rating on the stock in a research note on Thursday, March 6th.

About Spire Healthcare Group

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.